SWAlexander
Senior Member
- Messages
- 2,076
German Center for Infection Research:
EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV). The aim is to protect people from a range of serious diseases such as infectious mononucleosis, secondary diseases such as multiple sclerosis and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and certain types of cancer.
EBViously is based on a research project supported by Helmholtz Munich and the German Center for Infection Research (DZIF). The vaccine was developed by leading scientists in the field of Epstein-Barr virus research and the aim is now for the company to carry out professional product development.
Continue reading: https://www.eurekalert.org/news-releases/1068503
EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV). The aim is to protect people from a range of serious diseases such as infectious mononucleosis, secondary diseases such as multiple sclerosis and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and certain types of cancer.
EBViously is based on a research project supported by Helmholtz Munich and the German Center for Infection Research (DZIF). The vaccine was developed by leading scientists in the field of Epstein-Barr virus research and the aim is now for the company to carry out professional product development.
Continue reading: https://www.eurekalert.org/news-releases/1068503